Waystar (WAY) Q4 2025: AI-Driven Bookings Double, Securing Platform Leadership in Healthcare RCM

2026-02-17 | By EarningsIQ Research

Waystar’s Q4 saw a decisive inflection in AI adoption, with million-dollar-plus bookings more than doubling against historical averages. The company’s platform strategy, reinforced by the Iodine acquisition and deep AI integration, is translating into record retention, expanding client wins, and a robust backlog. With 2026 guidance pointing to sustained double-digit growth and strong margin discipline, Waystar’s execution signals a widening competitive moat in healthcare revenue cycle management (RCM).

Summary

  • AI-Infused Platform Drives Client Wins: Large deal volume and platform adoption surged as health systems prioritized integrated, outcome-driven RCM solutions.
  • Iodine Integration Accelerates Synergies: Cross-sell momentum and cost realization outpaced plan, expanding addressable market and operational leverage.
  • 2026 Outlook Anchored in Durable Growth: Record backlog and robust pipeline underpin confidence in double-digit expansion and compounding value creation.

Performance Analysis

Waystar delivered a standout Q4, crossing $1 billion in annual revenue for the first time and exceeding both revenue and EBITDA guidance. The quarter’s 24% year-over-year revenue growth was powered by a blend of organic expansion (12%) and the full-quarter contribution from the Iodine acquisition, which added $31 million in revenue. Subscription revenue outpaced volume-based streams, now comprising 55% of the business, and grew at a 38% pace year-over-year, reflecting the company’s deepening SaaS penetration in the provider segment.

Net revenue retention remained robust at 112%, with gross retention at 97% and a net promoter score above 70, signaling high embeddedness and client satisfaction. Adjusted EBITDA margin reached 43% for the quarter, benefiting from early realization of cost synergies tied to the Iodine integration. The company ended the year with $86 million in cash and a net leverage ratio of three times, down half a turn from the Iodine deal close, underscoring disciplined capital management.

  • Bookings Surge: Q4 saw record bookings, with million-dollar-plus deals more than doubling the three-year quarterly average, signaling accelerating demand for integrated AI-powered RCM.
  • AI Monetization Embedded: 30% of new bookings and 40% of revenue now stem from AI-powered solutions, demonstrating tangible client willingness to pay for automation and efficiency.
  • Operational Scale: Waystar processes over 7 billion transactions annually, touching 60% of US patients and underpinning its proprietary data advantage.

Waystar’s performance reflects not only strong organic execution but also successful acquisition integration, positioning the company for continued margin expansion and durable revenue growth in 2026.

Executive Commentary

"2025 was a defining year for Waystar. We crossed a billion dollars in revenue, exceeded both our revenue and EBITDA guidance, and achieved strategic milestones that strengthened our competitive position... We enter 2026 with strong momentum, a clear leadership position, and a platform we built to sustain durable, profitable growth while delivering exceptional value to our clients."

Matt Hawkins, Chief Executive Officer

"Our adjusted EBITDA margin of 43% for the fourth quarter benefits from approximately $2 million of realized acquisition cost synergies, reflecting 1% of margin improvement for the quarter... We expect to realize approximately $14 million of savings in 2026, which is over 90% of the committed $15 million we previously communicated and well ahead of the prior timeline."

Steve Oreskevich, Chief Financial Officer

Strategic Positioning

1. AI-First Platform as Competitive Moat

Waystar’s platform delivers end-to-end revenue cycle automation, integrating clinical and financial data to drive outcome-based workflows. With 50% of solutions leveraging AI, and nearly 40% of revenue derived from AI-embedded products, the company’s differentiation lies in proprietary data scale, closed-loop integration, and deployment depth. This infrastructure is core to delivering agentic AI—autonomous, outcome-driven automation that is increasingly non-negotiable for providers seeking efficiency and accuracy.

2. Iodine Acquisition—Expanding Mid-Cycle and Cross-Sell

The Iodine deal is proving transformative, extending Waystar’s reach into the mid-cycle—where payers deny 60 million claims annually—and adding over 1,000 hospital and health system clients with only 35% overlap. Integration is ahead of schedule, with 90% of targeted cost synergies expected in 2026. Cross-sell traction is already visible in both directions, expanding the total addressable market and reinforcing the unified platform value proposition.

3. Durable, Recurring Model with Embedded Growth

Waystar’s revenue model is anchored in highly recurring, consumption-driven contracts, tied directly to provider transaction volumes and patient utilization. The company’s 97% gross retention, low client concentration (top 10 clients at 11% of revenue), and strong net revenue retention create resilience and visibility. As AI adoption accelerates, Waystar’s ability to price to value and extend relationships is increasing, supporting sustained double-digit growth targets.

4. Distribution, Data, and Network Effects

With over one million provider connections and 100,000 live integrations, Waystar sits at the nexus of the payer-provider-patient ecosystem. Its scale and connectivity are self-reinforcing, as every transaction sharpens AI models and expands distribution reach. This network effect is a formidable barrier to entry for new entrants and point solutions, particularly as providers consolidate spend around trusted, interoperable platforms.

Key Considerations

This quarter’s results highlight several strategic levers reshaping the healthcare RCM landscape:

Key Considerations:

  • AI Monetization Pathways: Waystar is capturing value via new SKUs, price-to-value increases, and enhanced retention, as automation replaces manual workflows for clients.
  • Large Deal Momentum: The doubling of million-dollar-plus bookings signals a shift toward platform refresh cycles, with clients consolidating around end-to-end solutions rather than fragmented point tools.
  • Synergy Realization: Iodine integration is ahead of plan, with cross-sell and cost savings already contributing to margin expansion and pipeline depth.
  • Budget Dynamics: Providers are not carving out separate AI budgets, but are embedding AI in core RCM spend, favoring trusted partners with proven ROI and cybersecurity credentials.
  • Defensive Moat Widening: Network effects, proprietary data, and workflow stickiness are blunting the impact of new AI entrants and EHR vendors attempting to build their own RCM capabilities.

Risks

Waystar’s growth is exposed to macro healthcare utilization trends, as well as the pace of provider technology adoption and potential competitive disruption from EHR vendors or large tech entrants. While client retention and win rates are high, the company must continue to innovate and deliver measurable ROI to defend against point solution encroachment and evolving regulatory requirements. Integration risks from acquisitions, especially as the platform expands, require disciplined execution to avoid operational drag.

Forward Outlook

For Q1 2026, Waystar guided to:

  • 1% to 3% sequential revenue growth, with Q3 at the low end due to patient payment seasonality.
  • Gross margin consistent with 2025, at approximately 68%.

For full-year 2026, management raised guidance to:

  • Revenue of $1.274 billion to $1.294 billion (midpoint: $1.284 billion, up 17% YoY).
  • Adjusted EBITDA of $530 million to $540 million (midpoint: $535 million, 16% YoY growth, ~42% margin).

Management emphasized robust backlog and pipeline, with large deals expected to ramp over 6 to 18 months, supporting confidence in normalized double-digit growth and ongoing margin discipline.

Takeaways

  • AI-Driven Platform Shift: Waystar’s end-to-end, data-rich approach is winning share as providers consolidate around trusted RCM partners, with AI capabilities now central to client buying decisions.
  • Acquisition Integration Delivers: Iodine is already expanding cross-sell, operational leverage, and addressable market, with synergy realization ahead of plan.
  • Watch for Further Monetization: Investors should monitor the pace of new AI agent launches, continued upsell in the installed base, and the ability to sustain large deal momentum as the competitive landscape evolves.

Conclusion

Waystar exits 2025 with accelerating momentum, a widening competitive moat, and a clear path to durable, double-digit growth underpinned by AI leadership and disciplined execution. The platform’s embeddedness, data scale, and ability to monetize innovation position the company to compound value for shareholders and clients alike.

Industry Read-Through

Waystar’s quarter underscores a pivotal shift in healthcare RCM, as providers increasingly demand integrated, AI-powered platforms over fragmented point solutions. The rapid adoption of agentic AI, coupled with rising deal sizes and platform refresh cycles, signals that scale, data, and workflow integration are becoming table stakes for winning in this market. For incumbents and new entrants alike, the ability to deliver measurable ROI, regulatory-grade security, and seamless interoperability will separate winners from laggards. This dynamic is likely to ripple across adjacent healthcare IT sectors, accelerating consolidation and raising the bar for value delivery in mission-critical provider workflows.

WAY Healthcare Software AI RCM Acquisition Platform Automation